Newsfeeds Archive - Spark Newswire

2 minute read

What’s Going On With Small-Cap Cancer Focused XBiotech On Tuesday?

June 18, 1:08 PM

XBiotech reveals results from its Phase 1/Phase 2 1-BETTER Study for advanced pancreatic cancer, highlighting the safety and tolerability of Natrunix with the ONIVYDE + 5-Fluorouracil + Leucovorin regimen.

XBIT

1 minute read

XBiotech Shares Results From Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment For Advanced Pancreatic Cancer

By Benzinga Newsdesk

June 18, 11:48 AM

XBiotech (NASDAQ:XBIT) announced today data from its Phase 1/Phase 2 randomized, double-blind, placebo-controlled multi-center study for advanced pancreatic cancer. Known as 1-BETTER, the study examined Natrunix

XBIT

1 minute read

Movers

12 Health Care Stocks Moving In Monday’s Pre-Market Session

By Benzinga Insights

January 22, 9:05 AM

Gainers MSP Recovery (NASDAQ:LIFW) shares rose 23.1% to $1.49 during Monday’s pre-market session. The market value of their…

AEMD

2 minute read

XBiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke

By Benzinga Newsdesk

September 26, 9:05 AM

XBiotech Inc. (NASDAQ:XBIT) Announces that Hutrukin is being developed by XBiotech as a breakthrough therapy to reduce brain injury after stroke. The last subject in a randomized, open-label, placebo-controlled

XBIT

2 minute read

Movers

12 Health Care Stocks Moving In Tuesday’s After-Market Session

By Benzinga Insights

September 5, 5:31 PM

Gainers Akanda (NASDAQ:AKAN) shares increased by 13.5% to $0.63 during Tuesday’s after-market session. Trading volume for this security…

AIM

2 minute read

XBiotech Announces Enrollment Completion Of Phase II, Placebo Controlled, Multicenter Study For Natrunix In Pancreatic Cancer

By Happy Mohamed

August 30, 9:08 AM

XBiotech Inc. announced today completion of enrollment of the Phase II portion of its 1-BETTER study—a Phase I/II randomized, double-blind, placebo-controlled clinical study for Natrunix in combination with

XBIT

4 minute read

Why Doximity Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session

By Lisa Levin

May 17, 12:51 PM

Gainers

AGYS

3 minute read

Dow Jumps Over 100 Points; US Housing Starts Rise In April

By Lisa Levin

May 17, 9:45 AM

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.37% to 33,135.37 while the NASDAQ rose 0.39% to 12,391.68. The S&P 500, also rose, gaining, 0.45% to 4,128.33.

EVGO

2 minute read

XBiotech Announces First Subject Enrollment In Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke

By Happy Mohamed

April 17, 9:05 AM

XBiotech Inc. (NASDAQ:XBIT) has enrolled the first subject in a randomized, open-label, placebo-controlled dose escalation clinical study to evaluate safety and pharmacokinetics of Hutrukin. Hutrukin is

XBIT

5 minute read

Options

Stocks That Hit 52-Week Lows On Monday

By Benzinga Insights

November 28, 3:31 PM

On Monday, 79 companies reached new 52-week lows.

ADCT